ClinicalTrials.gg
CompletedNCT00887250Updated Jul 14, 2009Results posted

A Study to Investigate the Antihypertensive Efficacy of MK0954

A Phase 3 interventional study of losartan potassium and Comparator: losartan in Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2009-07-14.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
366
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies testing losartan in Hypertension — 5 open to participants now, 5 under way, 1 of them phase 3. Losartan · Hypertension.

Enrollment
12th of 65
366 · median 100
Started
1991
with 1 other
Phase 3
17 of 65
1 open now
Registered
18th of 65
by date
Lead sponsor
6 of 65
Merck Sharp & Dohme LLC

Among the 65 studies testing losartan in Hypertension, this one is the 12th largest by enrollment, is one of 2 that started in 1991, is one of 17 in phase 3, and was the 18th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

5 of the 65 studies testing losartan in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About losartan

Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing losartan in Hypertension, or all of them as a file.
02

Study summary

After a 4 week placebo period, patients were randomized to Placebo or Losartan 50 mg arms, after 6 weeks non-responders were up titrated to 100 mg losartan for the remaining 6 weeks. This study evaluated if losartan is more effective than placebo in lowering sitting diastolic blood pressure and is well tolerated in patients with mild to moderate hypertension.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has been diagnosed with mild to moderate hypertension (SDBP 95-115 mm Hg)
  • Patient has no medical problems or treatments that might effect their blood pressure

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating females
  • Patient has secondary hypertension or malignant hypertension
  • Sitting systolic blood pressure > 210 mm Hg
  • History of stroke
  • History of myocardial infarction with in past year
  • Current or prior history of heart failure
  • Known to losartan
  • Prior exposure to losartan
  • Patients known to be positive
  • Patient is abusing or has abused alcohol or other drugs within the past 4 years
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
366 participants (actual)

Study arms

  • Placebo comparator
    1

    Placebo

    Drug: Comparator: Placebo

  • Experimental
    2

    Losartan 50 mg for 12 weeks

    Drug: losartan potassium

  • Experimental
    3

    Losartan 50 mg titrated to 100 mg after 6 weeks

    Drug: Comparator: losartan

Interventions

  • 50 mg Losartan (MK0954) tablet taken once daily for 12 weeks.

    Also known as: MK0954

  • 50 mg tablet of Losartan (MK0954) taken once daily for 6 weeks, Non-responders will then have the dose up titrated to 100 mg for remaining 6 weeks.

    Also known as: MK0954

  • DrugComparator: Placebo

    Placebo to Losartan

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12

    Mean change from baseline in trough (24 hours post dose) SiDBP at Week 12

    Time frame: At baseline and at 12 weeks (24 hours post dose)

Secondary outcomes

  1. Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 6

    Patients with trough SiDBP \<90 mm Hg were in Category I, ≥90 but decreased at least 10 mm Hg were in Category II, and ≥90 and decreased less than 10 mm Hg were in Category III.

    Time frame: 24 hours post dose at Week 6

  2. Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 12

    Patients with trough SiDBP \<90 mm Hg were in Category I, ≥90 but decreased at least 10 mm Hg were in Category II, and ≥90 and decreased less than 10 mm Hg were in Category III.

    Time frame: 24 hours post dose at Week 12

  3. Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 6

    Mean change from baseline in trough (24 hours post dose) SiDBP at Week 6

    Time frame: At baseline and at 6 weeks (24 hours post dose)

  4. Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 6

    Mean change from baseline in peak (6 hours post dose) SiDBP at Week 6

    Time frame: At baseline and at 6 weeks (24 hours post dose)

  5. Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12

    Mean change from baseline in peak (6 hours post dose) SiDBP at Week 12

    Time frame: At baseline and at 12 weeks (6 hours post dose)

07

Results

Posted Jun 24, 2009
Limitations and caveats
Safety has been reported in the literature.

Participant flow

Patients were recruited at 22 sites in the United States. Prime Therapy Period: December, 1991 to August, 1992.

Participant flow — Overall Study
MilestonePlaceboLosartan 50 mgLosartan 50/100 mg
Started116127123
Completed98115110
Not completed181213
Withdrew: Adverse event307
Withdrew: Lack of efficacy961
Withdrew: Lost to follow-up231
Withdrew: Protocol violation221
Withdrew: Withdrawal by subject212
Withdrew: Patient uncooperative001

Outcome measures

PrimaryMean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12

Mean change from baseline in trough (24 hours post dose) SiDBP at Week 12

Time frame:
At baseline and at 12 weeks (24 hours post dose)
Reported as:
Mean · mm Hg
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12
mm HgPlaceboLosartan 50 mgLosartan 50/100 mg
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12-4.3 ± 6.7-7.9 ± 7.6-8.6 ± 7.7
SecondaryCategories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 6

Patients with trough SiDBP \<90 mm Hg were in Category I, ≥90 but decreased at least 10 mm Hg were in Category II, and ≥90 and decreased less than 10 mm Hg were in Category III.

Time frame:
24 hours post dose at Week 6
Reported as:
Number · Participants
Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 6
ParticipantsPlaceboLosartan 50 mgLosartan 50/100 mg
Category I143737
Category II82021
Category III926860
SecondaryCategories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 12

Patients with trough SiDBP \<90 mm Hg were in Category I, ≥90 but decreased at least 10 mm Hg were in Category II, and ≥90 and decreased less than 10 mm Hg were in Category III.

Time frame:
24 hours post dose at Week 12
Reported as:
Number · Participants
Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 12
ParticipantsPlaceboLosartan 50 mgLosartan 50/100 mg
Category I194037
Category II121824
Category III836757
SecondaryMean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 6

Mean change from baseline in trough (24 hours post dose) SiDBP at Week 6

Time frame:
At baseline and at 6 weeks (24 hours post dose)
Reported as:
Mean · mm Hg
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 6
mm HgPlaceboLosartan 50 mgLosartan 50/100 mg
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 6-3.5 ± 5.8-6.9 ± 7.0-7.9 ± 7.1
SecondaryMean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 6

Mean change from baseline in peak (6 hours post dose) SiDBP at Week 6

Time frame:
At baseline and at 6 weeks (24 hours post dose)
Reported as:
Mean · mm Hg
Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 6
mm HgPlaceboLosartan 50 mgLosartan 50/100 mg
Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 6-4.1 ± 6.9-9.7 ± 8.7-8.9 ± 8.7
SecondaryMean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12

Mean change from baseline in peak (6 hours post dose) SiDBP at Week 12

Time frame:
At baseline and at 12 weeks (6 hours post dose)
Reported as:
Mean · mm Hg
Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12
mm HgPlaceboLosartan 50 mgLosartan 50/100 mg
Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12-4.7 ± 7.9-9.5 ± 9.2-10.1 ± 8.6

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboLosartan 50 mgLosartan 50/100 mgTotal
Mean53.8 (26 to 78)53.2 (28 to 75)55.1 (28 to 76)54.0 (26 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLosartan 50 mgLosartan 50/100 mgTotal
Female424445131
Male748378235
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboLosartan 50 mgLosartan 50/100 mgTotal
Caucasian92104101297
Black17141647
Hispanic78419
Indian0101
Oriental0022
Sitting Diastolic Blood Pressure (SiDBP)
Sitting Diastolic Blood Pressure (SiDBP)(mm Hg)PlaceboLosartan 50 mgLosartan 50/100 mgTotal
Mean101.3 (95 to 115)102.2 (95 to 113)102.2 (95 to 114)101.9 (95 to 114)
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 1991, a primary completion of Aug 1992 and a completion of Nov 1992. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 16 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2009
First posted
Apr 23, 2009
Start
Dec 1991
Primary completionActual
Aug 1992
CompletionActual
Nov 1992
Results first posted
Jun 24, 2009
Last update
Jul 14, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00887250
First posted
Apr 23, 2009
Start date
Dec 1991
Primary completion
Aug 1992
Completion
Nov 1992
Results posted
Jun 24, 2009
Last update
Jul 14, 2009

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Losartan

Start the discussion